Kura Oncology CFO Marc Grasso resigns; Doyle named principal accounting officer, CEO Wilson principal financial officer

Kura Oncology, Inc.

CFO Marc Grasso resigns effective Feb 4, 2022 for family reasons; will provide up to 3 months advisory services with equity vesting.
Thomas Doyle appointed SVP Finance & Accounting/principal accounting officer effective Feb 7; base salary $333,500, bonus up to 35%, option for 39,281 shares and 8,390 RSUs.
CEO Troy Wilson appointed principal financial officer effective Feb 7.
Doyle's option vests over 48 months; RSU vests over 4 years; severance includes 9 months salary plus COBRA.
If within 12 months of change of control, Doyle receives lump sum of 9 months salary plus full target bonus.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Marc Grasso

Chief Financial Officer

KURA · Kura Oncology, Inc.

Effective: 2022-02-04
Filed: February 1, 2022, 6:59 PM ET

On January 26, 2022, Marc Grasso, M.D. notified Kura Oncology, Inc. (the “Company”) of his intention to resign from his positions as the Company’s Chief Financial Officer and Chief Business Officer, principal accounting officer and principal financial officer, effective as of February 4, 2022 (the “Separation Date”), in order to pursue opportunities closer to his family.

Appointed

Troy E. Wilson

Principal Financial Officer

KURA · Kura Oncology, Inc.

Effective: 2022-02-07
Filed: February 1, 2022, 6:59 PM ET

On January 31, 2022, the Board of Directors of the Company (the “Board”) appointed (i) Thomas Doyle, the Company’s Vice President, Finance, as the Company’s Senior Vice President, Finance and Accounting and as the Company’s principal accounting officer, and (ii) Troy E. Wilson, Ph.D., J.D., the Company’s President and Chief Executive Officer, as the Company’s principal financial officer, each effective as of February 7, 2022.

Appointed

Thomas Doyle

Senior Vice President, Finance and Accounting, Principal Accounting Officer

KURA · Kura Oncology, Inc.

Effective: 2022-02-07
Filed: February 1, 2022, 6:59 PM ET

On January 31, 2022, the Board of Directors of the Company (the “Board”) appointed (i) Thomas Doyle, the Company’s Vice President, Finance, as the Company’s Senior Vice President, Finance and Accounting and as the Company’s principal accounting officer, and (ii) Troy E. Wilson, Ph.D., J.D., the Company’s President and Chief Executive Officer, as the Company’s principal financial officer, each effective as of February 7, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Marc Grasso resigned as Chief Financial Officer at Kura Oncology, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On January 26, 2022, Marc Grasso, M.D. notified Kura Oncology, Inc. (the “Company”) of his intention to resign from his positions as the Company’s Chief Financial Officer and Chief Business Officer, principal accounting officer and principal financial officer, effective as of February 4, 2022 (the “Separation Date”), in order to pursue opportunities closer to his family.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Troy E. Wilson was appointed as Principal Financial Officer at Kura Oncology, Inc..

Action: appointed
Role: Principal Financial Officer

Exact text from the filing

On January 31, 2022, the Board of Directors of the Company (the “Board”) appointed (i) Thomas Doyle, the Company’s Vice President, Finance, as the Company’s Senior Vice President, Finance and Accounting and as the Company’s principal accounting officer, and (ii) Troy E. Wilson, Ph.D., J.D., the Company’s President and Chief Executive Officer, as the Company’s principal financial officer, each effective as of February 7, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Doyle was appointed as Senior Vice President, Finance and Accounting, Principal Accounting Officer at Kura Oncology, Inc..

Action: appointed
Role: Senior Vice President, Finance and Accounting, Principal Accounting Officer

Exact text from the filing

On January 31, 2022, the Board of Directors of the Company (the “Board”) appointed (i) Thomas Doyle, the Company’s Vice President, Finance, as the Company’s Senior Vice President, Finance and Accounting and as the Company’s principal accounting officer, and (ii) Troy E. Wilson, Ph.D., J.D., the Company’s President and Chief Executive Officer, as the Company’s principal financial officer, each effective as of February 7, 2022.

View on SEC.gov

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-024600

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.